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Hepatitis C virus (HCV) causes chronic hepatitis, which often results in the development of liver cirrhosis and hepatocellular carcinoma (HCC)
worldwide. In this study, we demonstrated that the non-structural protein NS3 of HCV enhances cyclooxygenase-2 (COX-2) gene promoter
activity, COX-2 mRNA expression, COX-2 protein production, and prostaglandin E2 (PGE2) release in HepG2 cells in a concentration-dependent
fashion. We also showed that transcription factor NF-κB is required for the activation of COX-2 regulated by NS3. In addition, multiple signaling
pathways are involved cooperatively in the expression of COX-2 activated by the viral protein in a calcium-independent manner, which requires
signaling components including JNK, ERK, and PKD2. A thorough investigation of mechanism involved in the activation of COX-2 regulated by
HCV would provide insights into our understanding the processes of liver inflammatory response and hepatocellular carcinoma development
caused by the viral infection and also into the development of novel therapeutics against HCV infection.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hepatitis C virus; NS3 protein; Cyclooxygenase-2; Gene regulation; Virus infection; Pathogenesis; Inflammation; PKC; JNK; ERK; Signaling pathwayIntroduction
Hepatitis C virus (HCV) is a major pathogen that causes
chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma
(HCC) with 170 million people infected worldwide (Saito et al.,
1990; Di Bishceglie, 1997). However, the exact mechanisms of
HCV-associated pathogenesis and carcinogenesis are largely
unknown.
HCV is a member of the flaviviridae family with a single-
stranded and positive-sense RNA genome of approximately
9.6 kb in length (Choo et al., 1989; Rice et al., 1996). The viral
RNA genome contains a single open reading frame flanked by
un-translated regions (UTR) at both 5′ and 3′ ends. A large viral
polyprotein precursor of about 3010 amino acids is translated
and sequentially cleaved by cellular and viral proteases into at
least 10 different proteins, including structural proteins (C, E1,⁎ Corresponding authors. Fax: +86 27 68754592.
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doi:10.1016/j.virol.2007.09.025E2, and p7) and non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) (Reed and Rice, 2000; Luo and
Colacino, 2004). Replication of HCV RNA occurs in the
cytoplasmic membrane-bound multiple-protein complex con-
taining the HCV RNA and non-structural proteins NS3 to NS5B
(Di Bishceglie, 1997; Luo and Colacino, 2004). Based on
genome sequence similarity, HCV is grouped into six major
genotypes and numerous subtypes (Tanaka et al., 1995).
NS3 is one of the viral serine proteases that is essential for
virus replication and would be a good target for antiviral drugs.
The serine protease is located in the N-terminal portion of NS3,
which is responsible for cleavage at the NS3/4A, NS4A/4B,
NS4B/5A, and NS5A/5B junctions. NS4A, a cofactor for NS3,
stabilizes it to augment its serine protease activity and is essential
for complete cleavage of the HCV polyprotein (Reed and Rice,
2000). The C-terminal portion of NS3 possesses the NTPase/
helicase activity, which is essential for viral RNA replication
(Kim et al., 1995).
In addition to its key role in the life cycle of HCV, NS3 is also
involved in viral persistence and hepatocarcinogenesis. NS3
Fig. 1. Roles of HCV proteins in the activation of COX-2 promoter. (A) HepG2
cells were co-transfected with 0.2 μg reporter plasmid pCOX-2-Luc containing
the luciferase gene under the control of COX-2 promoter and 0.4 μg plasmids,
pCMV-flag, pCMV-flag-Core, pCMV-flag-E1, pCMV-flag-E2, pCMV-flag-P7,
pCMV-flag-NS2, pCMV-flag-NS3, pCMV-flag-NS4A, pCMV-flag-NS4B,
pCMV-flag-NS5A, and pCMV-flag-NS5B, carrying individual genes of HCV,
respectively. Luciferase activity was measured as described in the Materials and
methods section. Results are expressed as the mean±sd of three independent
experiments performed in triplicate and normalized by β-galactosidase assay.
(B) Equal amount of pCMV-NS3 and pCMV-NS4A was transfected or co-
transfected, respectively, into HepG2 cells with reporter plasmid pCOX-2-Luc.
Results are expressed as the mean±sd of three independent experiments
performed in triplicate and normalized by β-galactosidase assay. ⁎, pb0.05
versus pCMV-flag.
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fibroblasts (Zemel et al., 2001). NIH3T3 cells constitutively
expressing truncated NS3 (aa 1–433) were more resistant to
Actinomycin D-induced apoptosis (Fujita et al., 1996). NS3
could also block transforming growth factor-α/Smad3-mediated
apoptosis (Cheng et al., 2004). In addition, NS3–NS4A complex
suppresses beta interferon (IFN-β) induction by inhibiting
retinoic acid-inducible gene I-mediated activation of IFN
regulatory factor 3 to help establish persistent HCV infection
(Foy et al., 2003; Breiman et al., 2005; Foy et al., 2005).
Recently it was reported that NS3 could inhibit the function of
tumor suppressor p53 in a sequence-dependent manner, which
partly interprets the different degree of oncogenic capacity of
different HCV isolates (Lin et al., 2006).
Cyclooxygenases (COX), including constitutively expressed
COX-1 and inducible COX-2, are the rate-limiting enzymes for
production of prostanoids (prostaglandins and thromboxanes)
from arachidonic acid. COX-2 has been categorized as a cellular
factor associated with inflammation (McAdam et al., 2000),
cellular growth (Williams et al., 2000), prevention of apoptosis
(McGinty et al., 2000), and tumorigenesis (Ambs et al., 1998).
It has also reported that COX-2 induces angiogenesis and is
essential for tumor growth (Tsujii et al., 1998). Increased
prostaglandin production and enhanced release of angiogenic
growth factor by COX-2 may induce neovascularization (Ambs
et al., 1998; Williams et al., 2000).
A number of investigations have demonstrated that viral
proteins can stimulate COX-2 expression. For examples,
latent membrane protein 1 of Epstein–Barr virus (EBV)
(Murono et al., 2001), X protein of hepatitis B virus (HBV)
(Lara-Pezzi et al., 2002), gp120 and Tat proteins of human
immunodeficiency virus (HIV) (Bagetta et al., 1998), and core
and NS5A proteins of HCV (Nunez et al., 2004) have been
reported to be able to activate COX-2 expression. We have
previously demonstrated that nucleocapsid protein (Yan et al.,
2006) and spike protein (Liu et al., 2006; 2007) of SARS-
associated coronavirus (SARS-CoV) were able to activate
COX-2 expression. However, the effects of other proteins of
HCV on the regulation of COX-2 protein expression and
inflammation are still unclear.
In this study, we investigated the roles of NS3 protein of
HCV in the activation of COX-2 expression and the mechan-
isms involved in such regulation. The effects of NS3 on COX-2
gene promoter activity, COX-2 mRNA expression, COX-2
protein production, and PGE2 release are determined. The roles
of transcription factor NF-κB and multiple signaling pathways
in NS3-activated COX-2 expression are also investigated and
discussed.
Results
NS3 of HCV activates COX-2 expression in HepG2 cells
It has been reported that HCV could induce the expression of
cyclooxygenase-2 in both clinic samples and in cell culture
system (Waris and Siddiqui, 2005) and that both core and NS5A
of HCV are required for the induction of COX-2 expression(Nunez et al., 2004). Here we investigated whether the rest
proteins of HCV play roles, if any, in the regulation of COX-2
expression. HepG2 cells were co-transfected with plasmid
(pCOX-2-Luc) carrying the reporter fusion gene, in which
luciferase gene is under the control of COX-2 promoter and
plasmids pCMV-Core, pCMV-E1, pCMV-E2, pCMV-P7,
pCMV-NS2, pCMV-NS3, pCMV-NS4A, pCMV-NS4B,
pCMV-NS5A, and pCMV-NS5B, carrying each of HCV
genes, core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, and
NS5B, respectively. Results from luciferase activity assay
showed that NS3 and Core proteins of HCV significantly
enhanced the expression of luciferase, while the rest of HCV
proteins tested in this study had no significant effect on the
fusion gene expression in HepG2 cells (Fig. 1A).
Considering the fact that NS4A protein always functions as
a cofactor in NS3 protease function including cellular
signaling pathways, we further checked whether NS4A plays
a role in NS3-regulated COX-2 expression. Cells were co-
transfected with plasmids carrying the NS3 gene and/or the
NS4A gene, respectively, along with pCOX-2-Luc. Results
from luciferase activity assay showed that the level of COX-2
promoter activity in the presence of NS3 was almost the same
as that in the presence of both NS3 and NS4A (Fig. 1B). These
results suggested that NS3 alone could activate the expression
COX-2 promoter in HepG2 cells without the cooperation of
NS4A.
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To further confirm the role of NS3 in the activation of COX-
2 expression, we determined the effects of different concentra-
tions of NS3 on the activation of COX-2 promoter. HepG2 cells
were co-transfected with the report plasmid pCOX-2-luc and
different concentrations of plasmid pCMV-NS3. Results from
luciferase activity assay showed that the level of COX-2
promoter activity increased as the concentration of NS3
increased, indicting NS3 stimulates COX-2 promoter in a
concentration-dependent fashion (Fig. 2A).
To determine the effects of NS3 on the activation of COX-2
mRNA expression, COX-2 protein production, and prostaglan-
din E2 (PGE2) generation, HepG2 cells were transfected with
different concentrations of pCMV-NS3. Results from RT-PCR
using COX-2-specific or β-actin-specific primers showed that
the levels of COX-2 mRNAwere increased as the concentration
of pCMV-NS3 increased, but the levels of β-actin mRNA
remained relatively constant (Fig. 2B). Results from western
blot analysis using antibody to COX-2 protein or to β-actin
protein revealed that the levels of COX-2 protein were
increased as pCMV-NS3 concentration increased, while β-
actin protein level was remained relatively unchanged (Fig.
2C). The production of PGE2 was assayed with the BiotrakFig. 2. Effects of NS3 protein on the expression of COX-2 in HepG2 cells. (A) Hep
pCMV-flag-NS3 as indicated. Luciferase activity was measured and results are expres
normalized by β-galactosidase assay. ⁎, pb0.05 versus pCMV-flag control. (B) He
indicated. Forty-eight hours post-transfection, total RNAwas isolated and used as tem
(low panel). (C) Forty-eight hours post-transfection, proteins were prepared from tran
protein (top panel) or to β-actin protein (low panel). (D) Levels of prostaglandin E2
Prostaglandin E2 Enzyme Immunoassay system. ⁎, pb0.05 versus pCMV-flag contProstaglandin E2 Enzyme Immunoassay system and results
indicated that the level of PGE2 was increased as the con-
centration of pCMV-NS3 increased (Fig. 2D). Taken together,
these results demonstrated that NS3 protein of HCV induces
COX-2 expression and PGE2 production in a dose-dependent
manner in HepG2 cells.
NF-κB is required for the activation of COX-2 gene regulated
by NS3
Activation of COX-2 gene relies on many consensus cis-
regulatory elements on its promoter, including two NF-κB
binding sites (Jijon et al., 2002) (Fig. 3A). To define the role of
NF-κB recognition elements in the activation of COX-2
regulated by NS3, three mutants (Mut1, Mut2, and Mut3) of
NF-κB binding site were generated by site specific mutagenesis
(Fig. 3A). Reporter plasmids were constructed, in which the
luciferase gene was under the control of Mut1, Mut2, and Mut3
promoter, respectively.
Plasmids carrying these mutant COX-2 promoters were then
co-transfected with pCMV-NS3 into HepG2 cells, respectively.
Results from luciferase assay showed that the two single muta-
tions (Mut1 and Mut2) reduced the level of COX-2 promoter
activation regulated by NS3 and the double mutation (Mut3)G2 cells were co-transfected with pCOX-2-Luc and different concentrations of
sed as the mean±sd of three independent experiments performed in triplicate and
pG2 cells were transfected with different concentrations of pCMV-flag-NS3 as
plates for RT-PCR using COX-2-specific (top panel) or β-actin-specific primers
sfected HepG2 cells and used for western blot analysis using antibody to COX-2
(PGE2) produced were measured from transfected HepG2 cells with the Biotrak
rol.
Fig. 3. Effects of NF-κB on the activation of COX-2 regulated by NS3. (A) Diagrams of COX-2 core promoter structures, including wild-type COX-2 promoter
(−891/+9) and three NF-κB mutant promoters, Mut1 (−447/−438, ΔNF-κB-a), Mut2 (−222/−213, ΔNF-κB-b), and Mut3 (−222/−213, −447/−438, ΔNF-κB-a
and -b). (B) HepG2 cells were co-transfected with 0.4 μg pCMV-flag-NS3 and 0.2 μg control plasmid or reporter plasmids, pCOX-2-Luc, pCOX-2-Mut1-Luc,
pCOX-2-Mut2-Luc, and pCOX-2-Mut3-Luc, respectively. The inducted level of luciferase activity was compared with that of vector control. Data are expressed as
mean±sd of three independent experiments. ⁎, pb0.05 versus control. †, pb0.05 versus wild type group. (C) HepG2 cells were transfected with a reporter vector,
in which the luciferase reporter gene is under the control of a NF-κB-binding sequence and plasmid pCMV-flag-NS3 at different concentrations as indicated.
Luciferase activity was measured and data represent the mean±sd of three independent experiments. ⁎, pb0.05 versus control. (D) HepG2 cells were transfected
with pCMV-flag or pCMV-flag-NS3 and then treated with or without 10 μM NF-κB inhibitor (MG132) for 24 h. Forty-eight hours post-transfection, total RNAwas
isolated and used as templates for RT-PCR using COX-2-specific (top panel) or β-actin-specific primers (low panel). (E) HepG2 cells were transfected with pCMV-
flag or pCMV-flag-NS3 and then treated with or without 10 μM MG132 for 24 h. Forty-eight hours post-transfection, proteins were prepared and used for western
blot analysis using antibody to COX-2 (top panel) or to β-actin (low panel). Blots were also normalized by measuring the amount of β-actin (Histogram). Bars are
mean of optical density ratio of each group, ⁎, pb0.05 versus vector control. †, pb0.05 versus pCMV-NS3.
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results suggested that NF-κB was involved in the regulation of
COX-2 gene expression. In subsequent experiment, cells were
transiently transfected with reporter plasmid, in which the
expression of luciferase gene is under the control of NF-κB-
binding element. Results showed that NS3 stimulated the NF-
κB-binding element activity in a dose-dependent manner (Fig.
3C). This result demonstrated that NF-κB was sufficient for the
activation of COX-2 expression regulated by NS3 protein.
NF-κB is a ubiquitously expressed transcription factor that
regulates the induction of genes involved in cellular immune
response and inflammatory function. To further confirm the
involvement of NF-κB in the activation of COX-2 regulated
by NS3, HepG2 cells were transfected with pCMV-NS3 and
treated with or without NF-κB inhibitor, MG132. Results from
RT-PCR analysis showed that MG132 significantly decreased
the level of COX-2 mRNA activated by NS3 (Fig. 3D).
Similar results were obtained when western blot analysis was
carried out, which indicated that MG132 significantly reduced
the level of COX-2 protein activated by NS3 (Fig. 3E). Theseresults demonstrated that transcription factor NF-κB was
required for the activation of COX-2 expression regulated by
NS3 protein.
Multiple signal transduction pathways are involved in the
activation of COX-2 expression regulated by NS3
Given the critical roles of COX-2 in liver inflammation and
carcinogenesis, it is important to understand the key signaling
pathways involved in the regulation of COX-2 expression in
human liver cell line. To delineate the signaling cascades
involved, HepG2 cells were transfected with pCMV-NS3 and
then treated with inhibitors of individual components of sig-
naling pathways.
Results from RT-PCR analyses showed that the level of
COX-2 mRNA activated by NS3 was suppressed by SP600125
(c-Jun inhibitor), GF109203 (PKC inhibitor), and PD98059
(MEK1/2 inhibitor), respectively, but not by LY294002 (PI3K
inhibitor), H89 (protein kinase A inhibitor), or SB203580
(SAPK2α/β/p38α/β MAPK inhibitor) (Fig. 4A). Similar
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formed, which showed that the level of COX-2 protein
expression regulated by NS3 was inhibited by SP600125,
GF109203, and PD98059, respectively, but not by LY294002,
H89, or SB203580 (Fig. 4B).
The roles of ERK and JNK in the activation of COX-2
mediated by NS3 protein were further determined by
introducing three dominant kinase-inactive mutants, mERK1,
mERK2, and mJNK, which can block corresponding kinase
activities by competing with endogenous kinases (Werlen
et al., 1998; Khoo et al., 2003). Cells were co-transfected with
pCMV-NS3, pCOX-2-Luc reporter, and each of these three
kinase mutants, respectively. Results from luciferase activity
assays showed that all three mutants reduced COX-2 promoter
activity in a dose-dependent manner, especially mERK2 and
mJNK (Fig. 4C). Taken together, these data suggested thatFig. 4. Involvement of signaling pathways in the activation of COX-2 expression
regulated by NS3. (A) HepG2 cells were transfected with pCMV-flag-NS3 (2 μg/
well of 6-well plate) and then treated with inhibitors of individual component of
signaling pathways, 50 μMGF109203 (PKC inhibitor), 30 μMSP600125 (c-JunN-
terminal kinase inhibitor), 50 μM PD98059 (MEK1/2 inhibitor), 25 μMLY294002
(PI3K inhibitor), 10 μM H89 (protein kinase A inhibitor), and 10 μM SB203580
(SAPK2α/β/p38α/βMAPK inhibitor), respectively. Total RNA was isolated from
treated cells and used as template forRT-PCRanalyses using primers for COX-2 (top
panel) or for β-actin (low panel). Blots were also normalized by measuring the
amount ofβ-actin (Histogram). Bars are mean of optical density ratio of each group.
⁎, pb0.05 versus vector control. †, pb0.05 versus pCMV-NS3. (B) HepG2 cells
were transfected with pCMV-flag-NS3 and treated with inhibitors, respectively.
Proteins were prepared from transfected cells and used for western blot analyses
using antibody to COX-2 (top panel) or toβ-actin (low panel). Blots were also
normalized bymeasuring the amount ofβ-actin (histogram).Bars aremeanof optical
density ratio of each group. ⁎, pb0.05 versus vector control. †, pb0.05 versus
pCMV-NS3. (C) HepG2 cells were co-transfected with pCMV-flag-NS3 (0.4 μg/
well of 24-well plate), pCOX-2-Luc (0.2 μg/well of 24-well plate), and dominant
negative mutants of ERK1/2, JNK at different concentrations as indicated, or control
vector. Luciferase activity wasmeasured and data are expressed asmean±sd of three
independent experiments. ⁎, pb0.05 versus vector control. †, pb0.05 versus
pCMV-NS3.ERK, JNK, and PKC were involved in NS3-regulated COX-2
activation.
NS3 protein of HCVactivates JNK and ERK signaling pathways
To evaluate the effects of NS3 protein of HCV on the
activation of JNK and ERK signaling cascades, we used
antibodies specific to the phosphorylated forms of the two
mitogen-activated protein kinases ERK1/2 and JNK. Results
from western blot and densitometry analyses showed that the
levels of phosphorylation of both JNK (Fig. 5A) and ERK1/2
(Fig. 5B) were significantly increased when NS3 protein was
present. These results suggested that NS3 plays a role in the
activation of JNK and ERK signaling pathways through phos-
phorylation of these two protein kinases.
NS3-activated COX-2 expression is calcium-independent and
involves PKD2 kinase
It is known that PKCs comprise a family of intracellular
serine/threonine-specific kinases. Depending on the type of
isoforms, activation of PKCs is typically initiated by Ca2+, lipid
second messengers, and/or protein activators. To elucidate
whether Ca2+ is involved in the expression of COX-2 regulated
by NS3, HepG2 cells were co-transfected with pCMV-NS3 and
pCOX-2-Luc and then treated with BAPAT/AM or EGTA at
different concentrations. Results from luciferase assays showed
that BAPAT/AM (Fig. 6A) and EGTA (Fig. 6B) had no
significant effect on the activity of COX-2 promoter regulated
by NS3, suggesting that Ca2+ was not involved in the induction
of COX-2 regulated by NS3.
We then extended our study to identify the specific isozymes
of PKC involved in NS3-regulated activation of COX-2 using
RNA interference (RNAi) approach. Small interfering RNA
(siRNA) molecules that specifically knock down genes
encoding for each PKC isozymes were used to study the
Fig. 5. Roles of JNK and ERK signaling pathways in NS3-mediated COX-2
expression. HepG2 cells were transfected with 2 μg of pCMV-flag-NS3 or
control plasmid. Proteins were prepared from transfected cells and the levels of
phospho-JNK and phospho-ERK1/2 were determined by western blot with
phospho-specific antibodies (top panels). Protein expression levels of non-
phospho-JNK and non-phospho-ERK in cell lysates were also detected as
controls (low panels). (A) Western blot results for phospho-JNK (top panel) and
JNK (low panel) and blots normalized by measuring the amount of phospho-
JNK/JNK (Histogram). Bars are mean of optical density ratio of each group. (B)
Western blot results for phospho-ERK (top panel) and ERK (low panel) and
blots normalized by measuring the amount of phospho-ERK/ERK (Histogram).
Bars are mean of optical density ratio of each group. ⁎, pb0.05 compared with
control.
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Liu et al., 2007). HepG2 cells were transfected with pCMV-NS3
and then treated with siRNAs, including siPKCδ, siPKCζ,
siPKCα, siPKCβ1, siPKD1, and siPKD2, respectively. Results
from western blot analysis using antibody to COX-2 protein
showed that siPKD2, but not other siRNAs tested, had a
significant effect on the activation of COX-2 protein expression
regulated by NS3 (Fig. 6C). These results suggested that PKD2
signaling pathway was involved in the activation of COX-2
regulated by NS3 protein.
Expression of PKD2 (Fig. 6D), PKCα (Fig. 6E), and PKCζ
(Fig. 6F) mRNA was also determined before and after knock
down by specific siRNA using RT-PCR analyses. Results
showed that expression of different PKC isoforms was
decreased significantly in the presence of PKC isoform-specific
siRNAs (siPKCα, siPKCζ, and siPKD2), but siCtrl (a controlsiRNA containing an irrelevant sequence to PKCs and no
homology to any human gene sequence) had no significant
effect on the expression of PKCs (Figs. 6D, E, and E). These
results indicated that various PKC isoform-specific siRNAs
worked efficiently in the assays and that among PKCs, only
PKD2 was involved in the activation of COX-2 regulated by
NS3 protein.
Discussion
COX-2 was reported to be highly expressed in liver
inflammation and carcinogenesis, thus representing a potential
target for drug intervention during these processes (Rahman et
al., 2001; Nunez et al., 2004; Aggarwal et al., 2006). Recent
study provided evidence that COX-2 is over-expressed in the
liver tissues of patients with chronic HCV infection, implying a
positive correlation with the fibrotic stage of liver disease.
Although the molecular basis for hepatocellular COX-2
expression in patients with chronic HCV infection remains to
be defined, there is evidence that core and NS5A proteins of
HCV can function as transcriptional transactivators for many
cellular genes (Kato et al., 2000; Reyes, 2002; Nunez et al.,
2004).
In the process of investigating the roles of additional proteins
of HCV in COX-2 expression during HCV infection, we found
that NS3 protein could induce COX-2 promoter activity, COX-2
mRNA expression, COX-2 protein production, and PGE2
generation in human liver cell line HepG2 in a concentration-
dependent fashion. These results suggested that NS3 protein of
HCV can also function as transcriptional transactivator for
cellular genes.
NF-κB has been reported to mediate COX-2 activation
induced by diverse stimulating agents. We demonstrated in this
study that NF-κB is also essential for NS3 protein-induced
COX-2 expression since mutations of binding sites for NF-κB
and the inhibitor of NF-κB could eliminate NS3 function in the
activation of COX-2.
Based on the findings that NS3 protein activates COX-2
expression and NF-κB is involved in such regulation, we further
investigated the roles of different MAP kinases on the activation
of COX-2 regulated by NS3. Our results demonstrated that
ERK, JNK, and PKC were involved in the activation of COX-2
regulated by NS3 since inhibition of each of those kinases
abolished the expression of COX-2 activated by NS3. We also
observed that inhibitors of PI3K, protein kinase A, and
SAPK2α/β/p38α/βMAPK had no effect on NS3-activated
COX-2 expression. Using RNA interference approach, we
further found that the induction of COX-2 by NS3 required the
atypical isoform PKD2 since PKD2 specific siRNA inhibited
COX-2 protein expression activated by NS3 and siRNA
specific to other PKC isoforms had no effect on NS3-induced
COX-2 expression.
Many viral proteins can induce multiple signaling pathways,
which may crosstalk with each other or converge on common
downstream effectors (Chen et al., 2003). In embryonic kidney
cells, the latent membrane protein-1 of EBV induced COX-2
expression through MAPK, JNK/AP-1, and JAK/STAT
Fig. 6. Effects of PKC signaling pathway on NS3-mediated COX-2 expression. HepG2 cells were co-transfected with 0.4 μg pCMV-flag-NS3 and 0.2 μg pCOX-2-
Luc. Forty hours post-transfection, cells were treated with BAPAT/AM (A) or EGTA (B) at different concentrations as indicated for 8 h. Luciferase activity was
measured and results are expressed as the mean±sd of three independent experiments performed in triplicate and normalized by β-galactosidase assay. (C) HepG2
cells were co-transfected with 0.4 μg pCMV-flag-NS3 or 2 μg pCMV-flag and 1 μg plasmids expressing siRNA specific to PKCδ, PKCζ, PKCα, PKCβ1, PKD1,
PKD2, and siCtrl, respectively. Proteins were prepared and used in western blot for detection of COX-2 (top panel) and β-actin protein (low panel). Western blots were
normalized by measuring the amount of COX-2/β-actin and bars are mean of optical density ratio of each group (histogram). ⁎, pb0.05 versus vector control.
†, pb0.05 versus pCMV-NS3. (D) Expression of PKD2 mRNA in the presence or absence of siRNAwas determined by RT-PCR for PKD2 (top panel) or for β-actin
(low panel). (E) Expression of PKCα mRNA in the presence or absence of siRNA was determined by RT-PCR for PKCα (top panel) or for β-actin (low panel).
(F) Expression of PKCζ mRNA in the presence or absence of siRNAwas determined by RT-PCR for PKCζ (top panel) or for β-actin (low panel). For better view, the
results were shown in histograms and bars are mean of optical density ratio of each (lower panels). ⁎, pb0.05 versus siCtrl.
67L. Lu et al. / Virology 371 (2008) 61–70signaling pathways and required the transcription factor NF-κB
(Saunders et al., 2001).
Our results in this study suggested that the NS3 of HCV
regulates multiple signaling pathways, such as ERK, JNK, and
PKD2, to control the activity of transcription factor NF-κB,
which in turn to activate the expression of COX-2 that may
induce host inflammatory response and, perhaps, carcinogen-
esis. A thorough understanding of COX-2 gene expression
regulated by the NS3 protein of HCV would provide insights
into the development of novel therapeutics and into our
understanding of liver inflammation and cancer development
caused by HCV infection.Materials and methods
Plasmids, antibodies, and reagents
SB203580, PD98059, LY294002, SP600125, GF109203,
H89, EGTA, MG132, DTT, fura-2/acetoxymethyl ester (AM),
and pluronic-F127 were purchased from Sigma Chemical Co
(St. Louis, MO, USA). All protein kinase inhibitors were
dissolved in DMSO and used at a final concentration of 50 μM
for PD98059, 10 μM for SB203580, 50 μM for GF109203,
30 μMfor SP600125, 25 μMfor LY294002, 10 μMfor H89, and
10 μM for MG132. Antibody against COX-2 was from Cayman
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for ERK, phospho-ERK, JNK, and phospho-JNK were
purchased from Santa Cruz Biotechnology, Inc (Santa Cruz,
CA, USA).
Luciferase reporter vector (pGL3) containing a COX-2
promoter region (−891/+9), its truncation mutants, and site
specific mutants were constructed previously (Zhu et al., 2002).
A NS3 construct was created by RT-polymerase chain reaction
(RT-PCR) amplification of the open reading frame from
HCV 2b. To create NS3-encoding vectors, the NS3 gene was
amplified using the following primers: 5′-AAAGGATC-
CATGGCGCCCATCACG-3′ (sense) 5′-CCCGAATTCC-
TAAGTGACGACCTCTAGGTC-3′ (antisense), in which
BamHI and EcoRI sites were introduced, respectively. The
polymerase chain reaction (PCR) product was cloned into
BamHI and EcoRI sites of pCMV-tag2B to generate plasmid
pCMV-NS3, in which NS3 protein was tagged by FLAG. The
resulting construct was confirmed by DNA sequencing. Mutants
of ERK1 and ERK2 were gifts from Dr. Cobb (University of
Texas Southwestern Medical Center) and a mutant of JNK was a
gift from Dr. Karin (University of California at San Diego, San
Diego, CA, USA). PKC siRNA vectors were constructed by
ligating the corresponding pairs of oligonucleotide to pSilencer
2.0 (Ambion, Inc., Augustin, TX, USA) based on the sequences
described previously (Storz et al., 2004).
Cell culture
The human hepatoma cell line HepG2 was grown in
Dulbecco's modified Eagle's medium supplemented with 10%
fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomy-
cin sulfate at 37 °C in a 5% CO2 incubator.
Transient transfection and luciferase reporter gene assays
Cells were plated at density of 4.0×105 cells per 24-well plate
or 6-well plate and grown to the confluence reaching about 80%
at the time of transfection. Cells were co-transfected with 0.4 μg
of plasmid pCMV-NS3 together with 0.2 μg plasmid containing
luciferase reporter and 0.2 μg of the pCMV-β-galactosidase
plasmid, using Sofast™ transfection reagent (Xiamen Sunma
Biotechnology Co. Ltd., China) according to the protocol pro-
vided by the manufacturer. In all co-transfection experiments,Table 1
Summary of sequences of primers used for RT-PCR in this study
Gene Product size (bp) Primer sequence
F-COX-2 667 TACAATGCTGA
R-COX-2 ACTGATGCGTG
F-β-actin 561 ATGATATCGCC
R-β-actin CGCTCGGTGA
F-PKD2 723 CACTGCCAATG
R-PKD2 ACTGAGCGGC
F-PKCα 284 GCCTATGGCGT
R-PKCα TTGGGCTTGAA
F-PKCζ 573 CTCCTGGTGCG
R-PKCζ GTTGTCGGTGAappropriate vector DNA was used to ensure similar DNA con-
centrations in all conditions. Twenty-four hours post-transfec-
tion, cells were serum-starved for another 24 h before being
harvested. Harvested cells were lysed with luciferase assay cell
culture lysis reagent (Promega,Madison,WI, USA). Cell lysates
and luciferase assay substrate (Promega) were mixed and light
intensity was detected by the luminometer (Turner T20/20).
Assays were performed in triplicate and expressed as means±sd.
All transfections included aβ-galactosidase expression vector to
serve as an internal control.
Semiquantitative RT-PCR analysis
Total RNA was isolated using a TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and reverse-transcribed with oligo(dT)
primer. PCR was performed in 25 μl reactions with the primer
pairs (20 μM) described in Table 1. β-Actin specific primers
were run in all reactions as an internal control. The PCR
products were amplified for 28 cycles. The selected cycle
number was chosen to stop the PCR reaction during its log
phase to ensure availability of all reagents. Additional RT-PCR
related information is summarized in Table 1. PCR products
were analyzed by electrophoresis on 1% agarose gel containing
ethidium bromide.
Western blot analysis
Whole-cell lysates were prepared by lysing HepG2 with
radioimmune precipitation buffer (50 mM Tris, pH7.5, 150 mM
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate [SDS], 1 mM sodium formate, 1 mM
phenylmethylsulfonyl fluoride, and 10% cocktail protease
inhibitor [Roche]). Cells were washed with ice-cold PBS,
collected by centrifugation, and pellets were resuspended in
RIPA buffer described above for 30 min on ice and vortexed for
10 s. Lysates were centrifuged at 12,000 rpm for 10 min. The
supernatants were boiled for 5 min in SDS–polyacrylamide gel
electrophoresis (PAGE) sample buffer. One hundred micro-
grams of cultured cell lysates was subjected to 12% SDS–
PAGE gel. Gels were electroblotted onto a nitrocellulose
membrane in 25 mM Tris, 192 mM glycine, and 20% methanol
by electrophoresis. Nonspecific IgGs were blocked with 5%
nonfat dried milk before being probed with antibodies used in(5′ to 3′) Tm (°C) Accession no.
CTATGGCTAC 55 NM_000963
AAGTGCTG
GCGCTCG 55 NM_001101
GGATCTTCA
CCACCTA 56.7 NM_016457
GGAACGA
CCTGT 52.7 NM_002737
TGGTG
GTTGAA 56 NM_002744
TGATGTCG
69L. Lu et al. / Virology 371 (2008) 61–70this study. After an additional washing step with blocking
buffer, immunoblots were visualized with the ECL detection
system (Pierce, Rockford, IL, USA).
Intracellular PGE2 measurements
Subconfluent HepG2 cells were transiently transfected
various amounts of pCMV-NS3. Forty-eight hours post-
transfection, culture cells were washed thoroughly with cold
phosphate-buffered saline, pH7.4, collected by centrifugation,
and pellets were resuspended in PBS pH7.4 containing 0.01%
Triton X-100, 0.01% EDTA, and 10% cocktail protease
inhibitor (Roche). Cell membranes were broken to release
intracellular PGE2. PGE2 levels were then assayed with the
Biotrak Prostaglandin E2 Enzyme Immunoassay system (R&D
Systems) according to the manufacturer's protocol.
Statistical analysis
All experiments were reproducible and were carried out in
duplicate or quadruplicate. Each set of experiments was repeated
at least three times with similar results, and a representative one
is shown. The results are presented at the means±sd. Student's t
test for paired samples was used to determine statistical sig-
nificance. Differences were considered statistically significant at
a value of P≤0.05. In all cases where comparative data are
presented, the autoradiographic images originated from the same
exposure of the same gel: in some cases, for clarity of pre-
sentation, lanes containing samples not germane to this study
were removed.
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